about
Targeting neuropilin-1 in human leukemia and lymphomaGelatinase-mediated migration and invasion of cancer cellsThe levels of trypsinogen isoenzymes in ovarian tumour cyst fluids are associated with promatrix metalloproteinase-9 but not promatrix metalloproteinase-2 activationAn unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment.Human Siglec-10 can bind to vascular adhesion protein-1 and serves as its substrateIntegrin-binding peptides derived from phage display libraries.Steps toward mapping the human vasculature by phage display.Identification of novel prostate-specific antigen-binding peptides modulating its enzyme activity.Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins.Peptide-mediated delivery of therapeutic and imaging agents into mammalian cells.Use of intein-directed peptide biosynthesis to improve serum stability and bioactivity of a gelatinase inhibitory peptide.A tripeptide mimetic of von Willebrand factor residues 981-983 enhances platelet adhesion to fibrinogen by signaling through integrin alpha(IIb)beta3.Stabilization of the activated alphaMbeta2 integrin by a small molecule inhibits leukocyte migration and recruitment.Novel peptide inhibitors of human kallikrein 2.Combinatorial targeting of the macropinocytotic pathway in leukemia and lymphoma cells.A chimera of green fluorescent protein with gelatinase binding and tumor targeting peptide.Vascular ligand-receptor mapping by direct combinatorial selection in cancer patients.Combinatorial targeting and discovery of ligand-receptors in organelles of mammalian cellsIsolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phage display library.Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library.Cell-surface interactions of echovirus 22.Role of leukemia cell invadosome in extramedullary infiltration.In vivo targeting of activated leukocytes by a β2-integrin binding peptide.Peptide inhibition of catalytic and noncatalytic activities of matrix metalloproteinase-9 blocks tumor cell migration and invasion.Peptides in cell adhesion: powerful tools for the study of integrin-ligand interactions.Identification of novel peptide inhibitors for human trypsins.Alpha v integrins as receptors for tumor targeting by circulating ligands.A polymeric form of fibronectin has antimetastatic effects against multiple tumor types.Metabolism and serum binding of RU 486 in women after various single doses.Characterization of a tumor-associated serine proteaseLiquid-chromatographic determination of beta 2-microglobulin, alpha 1-acid glycoprotein, and albumin in urineHuman colon carcinoma, fibrosarcoma and leukemia cell lines produce tumor-associated trypsinogenCyst fluid of ovarian cancer patients contains high concentrations of trypsinogen-2Time-resolved immunofluorometric assays for trypsinogen-1 and 2 in serum reveal preferential elevation of trypsinogen-2 in pancreatitisHuman ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinaseDetection of trypsin- and chymotrypsin-like proteases using p-nitroanilide substrates after sodium dodecyl sulphate polyacrylamide gel electrophoresisTumor-associated trypsin participates in cancer cell-mediated degradation of extracellular matrixCharacteristics of soluble tumour-derived proteins that inhibit natural killer activitySerum samples from pancreatectomized patients contain trypsinogen immunoreactivityVascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction
P50
Q24620098-D945D726-6D2B-426F-B8B2-3878AC621622Q28252032-57994709-D72B-489F-A81F-ADD27545F642Q28365272-E1E750F5-AD2F-420D-99DD-887E08EC36B9Q30157382-790A9155-0AD9-4A3D-94CB-893DF171CFE1Q30497345-07B51755-205B-4690-9224-66AAC4227C1BQ30777071-B16A34E2-DFF7-4C25-A4E3-DA1A00446BBCQ30804451-24B412B5-7BB9-45F9-BAC5-408781525D1CQ30933370-1E6ED44D-7154-4E5E-8103-38C3F56D0959Q30951913-2A445C0A-69FC-4B88-9F5E-1D67515A0B89Q31114064-E58D1306-2754-423E-84BD-D2212655A593Q31130348-585563A4-3EC3-4D9A-9862-9971C5ACD289Q33216768-E825F888-CD44-41BA-A6FF-D0A4887FD4C6Q33234857-89240C9B-90D4-4451-87A6-30A4F9EFE6B9Q33235991-00B028F8-E7BC-4781-ACEC-BB87C88AE6FAQ33320806-A7AE8C14-2BA4-45AD-A8BB-8AA336032839Q33549996-AF59A1F0-2F90-4E23-BD11-3253181D689CQ34065835-614F1C80-E64B-4040-84F7-226CFC3E7441Q34236236-B5233793-5767-4A0E-AD35-DB6BC28E1CCDQ36233759-D01E5638-FAA2-4F24-9C4C-C38EA604D35DQ36697115-D451F220-C089-4AD6-8238-23C5F57F18BDQ36876854-E251FD35-D398-48A4-85A8-2852B678C5C3Q37373047-49B403C9-E134-465C-BDB9-295E6570ADB2Q39104106-F6F261D6-6BA7-49AF-A50E-2A711FF63B8FQ40559840-066C293E-D71E-4651-A98F-D11D8894E435Q41495975-24E86C57-EE4A-4979-84B4-2258483B8249Q43175517-30894622-FCFC-46D8-8285-1332C8996DF1Q44563360-9375CEB5-A8EE-44E9-A34F-6214832EB558Q46453807-608DF6DC-6D6B-40ED-951E-2ECC302B45C6Q64956056-778C4465-DD78-4BF1-BC3C-865FD7A65795Q67988522-B2F62E3C-65A1-4775-A90C-1DE01262600BQ68194458-23A38CA4-F7EE-4475-ABC7-36ACC3996888Q68198443-6214A501-43B4-485B-B7DC-7BDA0DBB39B3Q68499072-8BCCBDD9-5DD0-4419-BCD4-10BCF6A689E8Q68843848-A4BDFFDA-D979-4D99-8D9E-31744F572391Q69220644-B99EDD93-D280-47EA-A07C-86BF636B4047Q69700362-64B8E21E-3D53-4712-B55C-2D99BC6AA449Q70127589-9373B56B-85AC-4A54-A83E-E80F5055AD33Q70194089-DD551094-DD17-4C84-A120-58C8E03958DEQ71404043-61E2F17F-5BB1-4AB0-B9ED-2BB8E5598EC1Q73071887-41E7F6EC-B41C-4F25-926E-13D913B7974E
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Erkki Koivunen
@ast
Erkki Koivunen
@en
Erkki Koivunen
@es
Erkki Koivunen
@nl
Erkki Koivunen
@sl
type
label
Erkki Koivunen
@ast
Erkki Koivunen
@en
Erkki Koivunen
@es
Erkki Koivunen
@nl
Erkki Koivunen
@sl
prefLabel
Erkki Koivunen
@ast
Erkki Koivunen
@en
Erkki Koivunen
@es
Erkki Koivunen
@nl
Erkki Koivunen
@sl
P108
P106
P108
P31
P496
0000-0002-6443-9595